Webcasting
    Abstracts
    Registration
    Accommodation
    Contact
     Home
     Welcome Note
     Scientific Committee
     Faculty list
     Timetable
     Scientific Program
     Poster Presentation Schedule
         Group A
         Group B
         Poster Presentation Guidelines
     Congress Award
         Awardees
     Registration
     Accommodation
         Hilton Athens
         Divani Caravel Hotel
         Stratos Vassilikos Hotel
         Golden Age Hotel
         Best Western Ilisia
     Accompanying Persons Program
     Sponsorship & Exhibition
     Sponsors
     Invitation Letter
     CME
         previous CME
     Webcasting
     CURy 2009
     General Information
         Before you travel...
     About Athens
     Italian Agent
     Contact Us
The 3rd World Congress on
Controversies in Urology (CURy)
Hilton Hotel, Athens, Greece, February 25-28, 2010
 
  Scientific Program Print
       
Friday, February 26, 2010
     
Session 1
 
 
PROGRESS IN MINIMALLY-INVASIVE SURGERY (MIS):
IS LAPARO-ENDOSCOPIC-SINGLE-SITE SURGERY (LESS) HERE TO STAY?
An unrestricted educational grant by Olympus Medical Systems Europa (GMBH)
08:30-10:00
     
Chairpersons:
   
J.-U. Stolzenburg, Germany & E. Liatsikos, Greece
  

 

Welcome and Introduction
J.-U. Stolzenburg, Germany
   
LESS: Instrumentation and evaluations
E. Liatsikos, Greece
  
LESS: Radical prostatectomy
F. Gaboardi, Italy
  
LESS: Transvaginal access
A. Alcaraz, Spain
  
LESS and its future: Tumor nephrectomies
J.-U. Stolzenburg, Germany
  
LESS: In gynecology
F. Fanfani, Italy
     
LESS: In general surgery
H. Weiss, Austria
   
Summary and Discussion
J.-U. Stolzenburg, Germany
  
    
  
Session 2

PROSTATE CANCER: PSA FAILURE AFTER TENTATIVE CURATIVE TREATMENT

08:30-10:00
 
Capsule:
Are there new strategies in the approach to failure of curative therapy?
Chairpersons:
L. Klotz, Canada & V. Rombis, Greece
         
08:30-08:35
Welcome
V. Rombis, Greece
 
08:35-08:45
What is the correct PSA threshold to define failure after surgery and irradiation?
J. Moul, USA
      
08:45-08:55
   
Evaluation of rising PSA
Role of biopsy: L. Boccon-Gibod, France
     
08:55-09:30
08:55-09:05
 
 
09:05-09:20
 
 
 
09:20-09:30
Rising PSA after radical prostatectomy
Management with X-ray therapy (XRT): When, to whom, how much?
R. Burette, Belgium
 
Hormonal therapy: When to initiate?
Speaker: Z. Dotan, Israel
Discussant: J. Anderson, UK
 
Is there a place for surveillance?
L. Klotz, Canada
     
09:30-10:00
09:30-09:40
 
 
 
09:40-09:50
 
 
 
09:50-10:00
 
 
Rising PSA after brachytherapy / radiation
Management with surgery: When, to whom?
Speaker: J. Anderson, UK
Discussant: J. Moul, USA
 
Management with hormonal therapy: Early vs. delayed
Speaker: F. Debruyne, UK
Discussant: S. Egawa, Japan
 
Role of minimally invasive salvage therapies, i.e. Cryo, HIFU, photodynamic therapy
Z. Symon, Israel
      
     
10:00-10:30 Coffee Break
      
Session 3
   
MEASURING OUTCOMES IN OVER-ACTIVE BLADDER (OAB): PAST, PRESENT AND FUTURE
An unrestricted educational grant by Astellas Pharma Europe Ltd.
10:30-12:00
Chairperson:
D. de Ridder, Belgium
      
10:30-11:00
 
 
Debate: Urodynamics remain the gold standard for assessment and measurement
Pro: A. Apostolidis, Greece
Con: P. Radziszewski, Poland
 
    
11:00-11:30
 
 
Debate: Patient reported outcomes are the most important and relevant way of measuring success
Pro: E. Costantini, Italy
Con: M. Speakman, UK
 
   
11:30-12:00
 
 
 
Debate: The use of biomarkers will become standard in the management of OAB in the future
Pro: C. Fowler, UK
Con: F. Cruz, Portugal
      
    
       
Session 4
   
BLADDER CANCER: NON-MUSCLE INVASION
An unrestricted educational grant by Kyowa Hakko Kirin
10:30-12:00
Capsule: Recurrence under treatment: What are the different options?
Chairpersons: J. Palou, Spain & A. Skolarikos, Greece
  
         
10:30-10:40
  
10:40-12:00
  
 
 
 
 
 
 
  
Opening remarks
   
Panel discussion & Case study for:
  
Immediate treatment: When? For which patients?
 
Recurrence under treatment: What are the different options?
 
Prognostic factors
 
Panel:
M. Brausi, Italy
F. Witjes, The Netherlands
W. Oosterlinck, Belgium
        
            
Session 5
  
DISCUSSION ON KEY CONTROVERSIES IN THE MANAGEMENT OF PROSTATE CANCER
Satellite Symposium by Astellas Pharma Europe Ltd.
12:00-13:30
Chairperson: L. Boccon-Gibod
    
Introduction
Chairperson
 
Multidisciplinary care in prostate cancer: What is the added value?
B. Tombal, Belgium
 
Testosterone monitoring in prostate cancer: Is it important?
C. Schulman, Belgium
 
Early management of prostate cancer: When and how?
J. Irani, France
 
Treatment of advanced prostate cancer: Can we reduce the impact on the patient's quality of life?
T. Oliver, UK
 
Discussion and take home messages
Chairperson, Faculty and Participants
    
         
13:30-14:30 Lunch Break
           
Session 6
  
CONTROVERSIES IN THE MANAGEMENT OF MALE LUTS: go with the flow or go for the patient
An unrestricted educational grant by Astellas Pharma Europe Ltd.
14:30-16:00    
Chairperson:
F. Debruyne, The Netherlands
        
14:30-15:00
It is about LUTS: controversies in the aetiology and diagnosis of LUTS in male patients
Patient case discussion: Chairperson & Audience
Evidence lecture: K. Stravodimos, Greece
     
15:00-15:30
Disrupted sleep in male LUTS patients: the neglected consequence of nocturia?
Patient case discussion: Chairperson & Audience
Evidence lecture: N. Stanley, UK
     
15:30-16:00
Male LUTS: is individualizing treatment against the flow?
Patient case discussion: Chairperson & Audience
Evidence lecture: P. van Kerrebroeck, The Netherlands
      
Session 7 TESTICULAR CANCER MANAGEMENT
14:30-16:00      
Capsule: Is there agreement on the treatment of stage-I testicular cancer?
Chairpersons: N. Fleshner, Canada & F. Sofras, Greece
     
14:30-14:50
Debate: Testicular-sparing surgery
For: N. Fleshner, Canada
Against: V. Matveev, Russia
   
14:50-15:15
Debate: Therapeutic options for stage-I seminoma
Surveillance: A. Bamias, Greece
Irradiation: H. Payne, UK
Chemotherapy: J. Bellmunt, Spain
   
15:15-15:40
Debate: Treatment options for stage-I non-seminomatous tumors
Surveillance: Z. Dotan, Israel
Surgery: J. Pinthus, Canada
Chemotherapy: J. Bellmunt, Spain
   
15:40-16:00
Retroperitoneal lymph node dissection (RPLND): Panel discussion
Post-chemotherapy only?
Experience with laparoscopic RPLND
Moderator: N. Fleshner, Canada
   
Panel:
A. Alcaraz, Spain
A. Bamias, Greece
V. Matveev, Russia
U. Studer, Switzerland
H. Payne, UK
  
           
16:00-16:30      Coffee Break
    
Session 8 PROSTATE CANCER PREVENTION, SCREENING AND EARLY DIAGNOSIS
16:30-17:30  
Capsule: Do we need to change the approach to prostate cancer screening and prevention?
Chairpersons: S. Egawa, Japan & Y. Fradet, Canada
      
16:30-16:40
 
 
16:40-16:50
 
 
16:50-17:00
 
 
17:00-17:10
 
 
Prevention rationale: What have we learned from the PCPT and REDUCE trails?
N. Fleshner, Canada
   
What are other possible prevention options?
S. Horie, Japan
   
Who should be screened? A critical assessment of the PLCO and ERSPC studies
P. Rischmann, France
  
The potential role of diagnostic markers
Y. Fradet, Canda
 
17:10-17:30
 
Discussion
 
     
Session 9
RENAL TUMORS: CASE DISCUSSION DEBATES
16:30-17:30
     
Capsule: Is there are standard treatment for all renal tumors?
Chairperson:
M. Marberger, Austria & C. Constandinidis, Greece
      
16:30-17:30
Panel:
A. Bamias, Greece
J. Fitzpatrick, UK
V. Matveev, Russia
M. Soloway, USA
C. Sternberg, Italy
J.-U. Stolzenburg, Germany

     

Saturday, February 27, 2010

Session 10
 
 
 
NON-MUSCLE INVASIVE BLADDER CANCER
Transurethral resection (TUR) quality control, How to improve outcomes,
Controversies in the management of T-1 disease
An unrestricted educational grant by General Electric (GE)
08:30-10:00  
Capsule: Can we reduce recurrence and progression of non-muscle invasive bladder cancer by improving TUR?
Chairpersons: M. Soloway, USA & J. Varkarakis, Greece
     
08:30-08:45
 
 
08:45-09:00
 
 
09:00-09:15
 
 
09:15-10:00
Quality control of transurethral resection of the bladder (TURB)
M. Soloway, USA
  
Can we improve TURB?
P. Geavlete, Romania
 
Improving outcomes and the role of Hexvix in reducing recurrence
D. Zaak, Germany
 
Controversies in T1 disease
When Re-transurethral resection of bladder tumor (TURBT) is indicated?
When a radical cystectomy should be considered?
Can we improve intravesical therapy?
H. Botto, France
M. Soloway, USA
F. Witjes, The Netherlands
  
 
    
Session 11
MEN'S HEALTH: Erectile dysfunction (ED) and testosterone deficiency (TD)
08:30-10:00  
Capsule: Current approaches to ED and TD: What new have we learned?
Chairpersons: D. Hatzichristou, Greece & E. Wespes, Belgium
   
 
 
 
08:30-08:45
 
 
08:45-09:00
 
Erectile dysfunction: Tip of the iceberg of cardio-vascular diseases
Sponsored by Itamar Medical
 
ED = Endothelial dysfunction?
E. Wespes, Belgium
 
Which ED patients are at cardiovascular risk?
R. Virag, France
     
  
09:00-09:10
 
 
09:10-09:20
 
 
09:20-09:30
Can we cure ED?
Daily dose vs. On demand PDE5-I after prostatectomy
A. Salonia, Italy
 
Shock wave treatment: A novel approach with a potential for cure
Y. Vardi, Israel
 
Implantation of penile prosthesis: A disappearing procedure?
D. Hatzichristou, Greece
     
  
 
  
09:30-09:45
  
 
09:45-10:00
 
 
Testosterone deficiency
Sponsored by Ferring Pharmaceuticals
  
Risks and benefits of testosterone treatment
M. Zitzmann, Germany
 
Which treatment for ED patients with TD?
C. Schulman, Belgium
  
         
10:00-10:30 Coffee Break and Poster Viewing
   
Session 12
  
STRATEGIES FOR OPTIMIZING OUTCOMES IN GENITOURINARY (GU) MALIGNANCIES
Supported by Novartis Oncology
10:30-12:00  
Capsule: Are there new strategies in the approach of bone metastasis in GU malignancies?
Chairpersons: G. Moutzouris, Greece & F. Saad, Canada
      
Introduction: Importance of bone health in GU cancers: G. Moutzouris, Greece
 
Optimal outcomes in metastatic renal cell carcinoma (RCC) and bladder cancerC. Schulman, Belgium
      
Optimal outcomes in metastatic prostate cancer: M. Colombel, France
  
Anticancer effects of zoledronic acid (ZOL): F. Saad, Canada
    
 
Questions & Answers:
 
Factors that contribute to optimal outcomes in advanced GU malignancies (value of bone health)
-Pain reduction
-Increased QoL
-Cost effectiveness
-Effective even in late-stage disease
  
Potential anti-cancer properties of bisphosphonates (BPs) in GU malignancies
-ZOL anticancer mechanism of action: Data in prostate, kidney and bladder cancers

   
 
       
Session 13
MINIMAL AND LOCALIZED PROSTATE CANCER
10:30-12:00
   
Capsule: Has active surveillance become a treatment option for selected patients?
Chairpersons:
J. Irani, France & A. Deliveliotis, Greece
     
10:30-11:00
 
 
Debate: Selecting patients for active surveillance: Should present criteria be enlarged or reduced?
Enlarged: L. Klotz, Canada
Reduced: J. Moul, USA
      
11:00-11:40
 
   
 
 
 
 
 
 
 
Debate: Triggers for therapy in patients on active surveillance
Prostate specific antigen (PSA) kinetics and diagnostic markers
Can magnetic resonance imaging and spectroscopy prove useful?
Can 5-Alpha-Reductase influence patients' selection?
   
Panel:
Y. Fradet, Canada
N. Fleshner, Canada
W. Oosterlinck, Belgium
M. Soloway, USA
 
 
11:40-12:00
 
 
 
Debate: Radiation + hormone: Is the survival benefit balanced by the side effects?
Combination therapy: H. Payne, UK
Radiation alone: Z. Symon, Israel
 
    
    
Session 14
 
 
GONADOTROPIN-RELEASING HORMONE (GnRH) RECEPTOR BLOCKADE: THE NEW APPROACH TO PROSTATE CANCER MANAGEMENT
An unrestricted educational grant by Ferring Pharmaceuticals
12:00-13:30
   
Capsule: What is new in hormonal therapy for prostate cancer?
Chairpersons:
    
J. Anderson, UK & I. Vakalopoulos, Greece
    
12:00-12:05
 
Welcome and Objectives
 
12:05-12:25
 
 
12:25-12:45
 
 
12:45-13:05
 
 
13:05-13:25
 
 
Clinical development of a new GnRH blocker:
B.-E. Persson, Switzerland
 
Firmagon vs. Leuprolide: What is the difference?
B. Tombal, Belgium
 
Which patients will benefit from GnRH blocker therapy?
J. Anderson, UK
 
Neoadjuvant/adjuvant hormonal treatment
H. Payne, UK
 
13:25-13:30
 
Conclusions
J. Anderson, UK 
  
  
    
Session 15
MALE URINARY INCONTINENCE
12:00-13:30
  
Capsule: Can we agree on a solution to all male urinary incontience?
Chairpersons: F. Cruz, Portugal & N. Sofikitis, Greece
   
    
12:00-12:10
 
 
12:10-12:20
 
How big is the problem and how should it be handled?
L. Boccon-Gibod, France
 
Incontinence after radiation therapy (RT) for prostate cancer?
D. de Ridder, Belgium
     
12:20-13:00
 
 
 
 
Surgical options: Pros and Cons
AUS: J. Heesakkers, The Netherlands
Invance: P. Dinis, Portugal
Obturator tapes: D. Waltregny, Belgium
ProAct balloons: P. Radziszewski, Poland
   
13:00-13:30
 
 
 
 
 
 
 
 
 
Clinical cases
Moderator: F. Cruz, Portugal
 
Panel:
L. Boccon-Gibod, France
D. de Ridder, Belgium
P. Dinis, Portugal
J. Heesakkers, The Netherlands
P. Radziszewski, Poland
D. Waltregny, Belgium
 
  
 
13:30-13:40
 
Best Abstract Award Ceremony
Sponsored by Pfizer Oncology
13:40-14:30 Lunch Break
    
Session 16
  
KEY CONTROVERSIES IN ADVANCED GENITOURINARY (GU) CANCERS
An unrestricted edcuational grant by Sanofi Aventis
14:30-16:00
   
Capsule: Can we improve outcomes for patients with advanced GU cancers?
Chairpersons: J. Fitzpatrick, UK & C. Sternberg, Italy
 
   
14:30-14:35
  
Opening and Welcome
C. Sternberg, Italy
 
  
14:35-14:50
 
 
14:50-15:15
 
 
15:15-15:35
 
 
15:35-15:55
  
Controversies concerning European and US screening studies
J. Fitzpatrick, UK
 
Management of advanced prostate cancer: Challenges and controversies - Asymptomatic patients and senior adults
A. Zlotta, Canada
 
Beyond docetaxel: When and whom to consider?
S. Oudard, France
 
Exploring the unmet needs in metastatic castrate-resistant prostate cancer (mHPRC): What does the future hold?
C. Sternberg, Italy
    
15:55-16:00
 
 
Summary
J. Fitzpatrick, UK
    
     
Session 17
   
ENDOUROLOGY & NEPHROLITHIASIS
An unrestricted educational grant by Karl Storz
14:30-16:00
Capsule: Is there a best approach to treat a kidney stone?
Chairperson: P. Geavlete, Romania & D. Mitropoulos, Greece
     
14:30-15:00
   
 
Debate: Supine vs. Prone position during percutaneous nephrolithotomy (PCNL)
Supine position: R. Scarpa, Italy
Prone position: P. Conort, France
    
15:00-16:00
 
Debate: Difficult situation: Is there a limit?
Moderator: M. Marberger, Austria
   
Panel:
P. Conort, France
R. Scarpa, Italy
A. Skolarikos, Greece
H. Winkler, Israel
    
 
   
16:00-16:30 Coffee Break and Poster Viewing
   
Session 18
     
BENIGN PROSTATIC HYPERPLASIA (BPH) SURGICAL MANAGEMENT
An unrestricted educational grant in part by American Medical Systems
16:30-18:00
   
Capsule: Green light (GL) laser session on the treatment of outflow obstruction
Chairpersons: G. Alivizatos, Greece & F. d'Ancona, The Netherlands
    
16:30-16:40
 
 
16:40-16:50
 
 
16:50-17:00
 
 
17:00-17:10
 
 
17:10-17:20
 
 
17:20-17:30
 
 
17:30-17:40
 
 
 
17:40-17:50
 
 
Why do we need an alternative to the gold standard and TURP in the first place?
G. Alivizatos, Greece
 
What evidence is provided by published papers that the GL laser is effective?
A. Bachmann, Switzerland
 
Can we treat big prostates and big middle lobes with the GL laser?
F. Gomez-Sancha, Spain
 
Tips, tricks and pearls for successful GL patient outcomes
F. d'Ancona, The Netherlands
 
No tissue, no biopsy with the GL laser: Is that a problem?
F. Schiefelbein, Germany
 
Patients under anticoagulation therapy and patients in retention: Can they be treated?
N. Barber, UK
 
Is the GL laser a better surgical treatment alternative to that of traditional TURP? What are the major differences in relation to other lasers?
F. Gomez-Sancha, Spain
 
Is it possible that in the future lasers may compete with medical treatment?
G. Alivizatos, Greece
    
17:50-18:00
 
Questions and answers    
  
  
   
Session 19
LOCALLY ADVANCED BLADDER CANCER: CASE DISCUSSION
16:30-18:00
   
Capsule: Can we adapt a solution to all patients will locally advanced disease?
Chairpersons: A. Zlotta, Canada & A. Antoniou, Greece
     
16:30-16:45
Neoadjuvant or adjuvant chemotherapy when the renal function is impaired: for some patients, for all patients, for no patients?
A. Bamias, Greece
     
16:45-17:00
Locally-advanced bladder cancer: When the margins are positive
M. Soloway, USA
   
17:00-18:00
Case discussion
Does surgery offer some hope of cure when the nodes are grossly positive?
Contraindications to neo-bladder reconstruction
Management of advanced bladder cancer with hydronephrosis and kidney failure
Moderator: A. Zlotta, Canada
   
Panel:
A. Bamias, Greece
Y. Fradet, Canada
W. Mansson, Sweden
M. Soloway, USA
U. Studer, Switzerland
  

     

Sunday, February 28, 2010

Session 20 URINARY DIVERSION
09:00-10:30    
Capsule: Is there a best urinary diversion? Can we improve selection?
Chairpersons: R. Hautmann, Germany & S. Horie, Japan
     
09:00-10:00
Urinary diversion following cystectomy for bladder cancer: Advantages and disadvantages
Conduits: M. Marberger, Austria
Orthotopic diversion in males: U. Studer, Switzerland
Orthotopic diversion in females: A. Stenzl, Germany
Continent cutaneous diversion: W. Mansson, Sweden
Anal sphincter diversion: H. Botto, France
       
10:00-10:25
Case discussion
Moderator: R. Hautmann, Germany 
  
Panel: 
H. Botto, France
W. Mansson, Sweden
M. Marberger, Austria
A. Stenzl, Germany
U. Studer, Switzerland
       
10:25-10:30
Conclusion
R. Hautmann, Germany   
      
   
10:30-11:00 Coffee Break and Poster Viewing
   
Session 21
 
 
LOOKING AT OUTCOMES
Surgery for bladder and prostate cancer
Open vs. Lap vs. Robotic
11:00-12:30   
Capsule: Open vs. Lap vs. Robotic: Is there a winner?
Chairpersons: A. Alcaraz, Spain, U. Studer, Switzerland & J. Ramon, Israel
   
11:00-11:50
 
 
 
 
 
 
 
 
 
 
 
11:00-11:15
11:15-11:30
11:30-11:45
Surgery for bladder cancer
Operative time and hospital stay
Operative complications
Lymph node dissection

Surgical margins
Cutaneous or orthotopic diversion
Progression free survival
Cancer-specific survival
Overall survival
Urinary continence

Potency preservation
      
Open: R. Hautmann, Germany; A. Zlotta, Canada
Lap: T. Piechaud, France
Robotic: J. Palou, Spain
  
11:50-12:00
Outcomes summary for bladder cancer: Open vs. Lap vs. Robotic:
A. Stenzl, Austria
  
12:00-12:50
 
 
 
 
 
 
 
 
 
 
12:00-12:15
12:15-12:30
12:30-12:45
 
Surgery for prostate cancer
Operative time and hospital stay
Operative complications
Lymph node dissection
Surgical margins
Progression free survival
Cancer-specific survival
Overall survival
Urinary continence
Potency preservation
 
Open: C. Barre, France; M. Soloway, USA
Lap: S. Egawa, Japan
Robotic: T. Piechaud, France
 
12:50-13:00
Outcomes summary for prostate cancer: Open vs. Lap vs. Robotic:
A. Alcaraz, Spain
  
 
    
13:00-13:30 Drinks & Sandwiches


Home   
Copyright © 2007 comtecmed.com. All rights reserved. Created by     WebStudio.co.il